×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OGEN – oragenics inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OGEN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/4
02:09 am
ogen
Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/27
02:07 am
ogen
Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/19
02:07 am
ogen
Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/18
08:30 am
ogen
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
Medium
Report
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
10/11
02:07 am
ogen
Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/9
07:30 am
ogen
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
Low
Report
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
10/8
08:47 am
ogen
EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate [Yahoo! Finance]
High
Report
EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate [Yahoo! Finance]
10/8
08:45 am
ogen
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
High
Report
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
10/31
09:15 am
ogen
Form DEF 14A ORAGENICS INC For: Oct 31
Medium
Report
Form DEF 14A ORAGENICS INC For: Oct 31
10/18
08:31 am
ogen
Form 8-K ORAGENICS INC For: Oct 18
Medium
Report
Form 8-K ORAGENICS INC For: Oct 18
10/16
10:31 am
ogen
Form 8-K ORAGENICS INC For: Oct 15
Medium
Report
Form 8-K ORAGENICS INC For: Oct 15
10/15
06:03 am
ogen
Form 8-K ORAGENICS INC For: Oct 11
Medium
Report
Form 8-K ORAGENICS INC For: Oct 11
10/9
07:31 am
ogen
Form 8-K ORAGENICS INC For: Oct 09
Low
Report
Form 8-K ORAGENICS INC For: Oct 09
9/20
09:16 pm
ogen
Form 4 ORAGENICS INC For: Sep 19 Filed by: GANDOLFO JOHN P
Low
Report
Form 4 ORAGENICS INC For: Sep 19 Filed by: GANDOLFO JOHN P
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/4
Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein”
56.0%
9/6 Form 8-K ORAGENICS INC For: Sep 06 21.4%
6/24 Form S-8 ORAGENICS INC 15.7%
5/20 Oragenics, Inc. Provides Development Update of AG013 for Oral Mucositis 13.8%
9/23 Oragenics, Inc. to Present Interim Data on AG013 at the European Society of Medical Oncology Congress 13.2%
2/7 Oragenics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference 7.5%
11/15 Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science Demonstrating First Complete Chemical Synthesis of Bicyclic Ring of a Mutacin 1140 Analog 5.6%
11/11 Oragenics, Inc. SVP of Discovery Research, Martin Handfield, Ph.D. to Be Featured Speaker at the International Conference on Microbial Research and Applications 3.5%
3/2 Form SC 13D/A ORAGENICS INC Filed by: KIRK RANDAL J 2.8%
9/25 Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013 Reaches Enrollment of 158 Patients 2.7%
9/6 Form 8-K ORAGENICS INC For: Sep 06 21.4%
6/24 Form S-8 ORAGENICS INC 15.7%
5/20 Oragenics, Inc. Provides Development Update of AG013 for Oral Mucositis 13.8%
9/23 Oragenics, Inc. to Present Interim Data on AG013 at the European Society of Medical Oncology Congress 13.2%
2/7 Oragenics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference 7.5%
11/15 Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science Demonstrating First Complete Chemical Synthesis of Bicyclic Ring of a Mutacin 1140 Analog 5.6%
11/11 Oragenics, Inc. SVP of Discovery Research, Martin Handfield, Ph.D. to Be Featured Speaker at the International Conference on Microbial Research and Applications 3.5%
3/2 Form SC 13D/A ORAGENICS INC Filed by: KIRK RANDAL J 2.8%
9/25 Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013 Reaches Enrollment of 158 Patients 2.7%
TOP News Decliners
10/22
Form 8-K ORAGENICS INC For: Oct 22
-20.0%
2/11 Form SC 13G/A ORAGENICS INC Filed by: INTRACOASTAL CAPITAL, LLC -10.4%
12/3 Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019 -6.9%
2/7 Form 4 ORAGENICS INC For: Feb 05 Filed by: KOSKI ROBERT C -6.5%
3/4 Form 10-K ORAGENICS INC For: Dec 31 -4.9%
9/30 Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019 -4.6%
9/25 Form 8-K ORAGENICS INC For: Sep 25 -4.3%
12/2 Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis -3.2%
1/24 Form SC 13D/A ORAGENICS INC Filed by: KOSKI FAMILY LP -3.2%
12/4 Form 8-K ORAGENICS INC For: Dec 04 -3.1%
2/11 Form SC 13G/A ORAGENICS INC Filed by: INTRACOASTAL CAPITAL, LLC -10.4%
12/3 Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019 -6.9%
2/7 Form 4 ORAGENICS INC For: Feb 05 Filed by: KOSKI ROBERT C -6.5%
3/4 Form 10-K ORAGENICS INC For: Dec 31 -4.9%
9/30 Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019 -4.6%
9/25 Form 8-K ORAGENICS INC For: Sep 25 -4.3%
12/2 Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis -3.2%
1/24 Form SC 13D/A ORAGENICS INC Filed by: KOSKI FAMILY LP -3.2%
12/4 Form 8-K ORAGENICS INC For: Dec 04 -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: